Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) has received an average rating of “Hold” from the seventeen analysts that are covering the firm, MarketBeat Ratings reports. Three research analysts have rated the stock with a sell rating, six have issued a hold rating, six have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $49.64.

A number of research firms have recently commented on IONS. Zacks Investment Research upgraded shares of Ionis Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $62.00 price objective for the company in a research note on Friday, October 27th. Needham & Company LLC reaffirmed a “buy” rating and issued a $64.00 target price on shares of Ionis Pharmaceuticals in a report on Tuesday, October 17th. Stifel Nicolaus reaffirmed a “hold” rating and issued a $50.00 target price on shares of Ionis Pharmaceuticals in a report on Friday, October 13th. Goldman Sachs Group, Inc. (The) reaffirmed a “sell” rating and issued a $30.00 target price on shares of Ionis Pharmaceuticals in a report on Friday, October 6th. Finally, BMO Capital Markets reaffirmed an “outperform” rating and issued a $69.00 target price on shares of Ionis Pharmaceuticals in a report on Monday, October 2nd.

WARNING: “Ionis Pharmaceuticals, Inc. (IONS) Given Average Recommendation of “Hold” by Brokerages” was published by American Banking News and is the property of of American Banking News. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international copyright and trademark law. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/11/01/ionis-pharmaceuticals-inc-ions-given-average-recommendation-of-hold-by-brokerages.html.

In other Ionis Pharmaceuticals news, COO B Lynne Parshall sold 16,118 shares of the stock in a transaction dated Wednesday, October 18th. The shares were sold at an average price of $65.00, for a total value of $1,047,670.00. Following the transaction, the chief operating officer now directly owns 33,526 shares of the company’s stock, valued at approximately $2,179,190. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Stanley T. Crooke sold 15,000 shares of the stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $52.00, for a total transaction of $780,000.00. Following the completion of the transaction, the chief executive officer now directly owns 43,014 shares in the company, valued at $2,236,728. The disclosure for this sale can be found here. Over the last three months, insiders sold 97,636 shares of company stock worth $5,665,565. Insiders own 2.13% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the business. Parallel Advisors LLC raised its holdings in Ionis Pharmaceuticals by 62.8% in the 2nd quarter. Parallel Advisors LLC now owns 2,073 shares of the company’s stock valued at $109,000 after acquiring an additional 800 shares during the period. Hanseatic Management Services Inc. raised its holdings in Ionis Pharmaceuticals by 1.2% in the 2nd quarter. Hanseatic Management Services Inc. now owns 3,481 shares of the company’s stock valued at $177,000 after acquiring an additional 41 shares during the period. The Manufacturers Life Insurance Company raised its holdings in Ionis Pharmaceuticals by 9.1% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 3,744 shares of the company’s stock valued at $190,000 after acquiring an additional 311 shares during the period. WFG Advisors LP raised its holdings in Ionis Pharmaceuticals by 77.2% in the 2nd quarter. WFG Advisors LP now owns 3,800 shares of the company’s stock valued at $193,000 after acquiring an additional 1,655 shares during the period. Finally, Cambridge Investment Research Advisors Inc. bought a new position in Ionis Pharmaceuticals in the 2nd quarter valued at about $222,000. 89.01% of the stock is currently owned by hedge funds and other institutional investors.

Ionis Pharmaceuticals (IONS) traded up 1.30% during trading on Wednesday, reaching $57.85. The company’s stock had a trading volume of 596,694 shares. The company’s 50 day moving average price is $56.68 and its 200 day moving average price is $51.46. The company has a market cap of $7.19 billion, a P/E ratio of 278.12 and a beta of 3.12. Ionis Pharmaceuticals has a 52 week low of $24.58 and a 52 week high of $65.51.

Ionis Pharmaceuticals (NASDAQ:IONS) last posted its quarterly earnings data on Tuesday, August 8th. The company reported ($0.09) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.06) by ($0.03). Ionis Pharmaceuticals had a return on equity of 15.52% and a net margin of 5.25%. The business had revenue of $104.15 million for the quarter, compared to analyst estimates of $93.29 million. During the same quarter in the prior year, the company earned ($0.47) earnings per share. The company’s quarterly revenue was up 170.7% on a year-over-year basis. On average, equities analysts anticipate that Ionis Pharmaceuticals will post ($0.14) earnings per share for the current fiscal year.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.

Analyst Recommendations for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.